[go: up one dir, main page]

MA31308B1 - Anticorps antisclerostine. - Google Patents

Anticorps antisclerostine.

Info

Publication number
MA31308B1
MA31308B1 MA32274A MA32274A MA31308B1 MA 31308 B1 MA31308 B1 MA 31308B1 MA 32274 A MA32274 A MA 32274A MA 32274 A MA32274 A MA 32274A MA 31308 B1 MA31308 B1 MA 31308B1
Authority
MA
Morocco
Prior art keywords
antibodies
sclerostine
fight
bone
osteoporosis
Prior art date
Application number
MA32274A
Other languages
Arabic (ar)
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31308B1 publication Critical patent/MA31308B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés et chimériques qui se lient spécifiquement à la sclérostine humaine et sont caractérisés en ce qu'ils présentent une affinité élevée et d'importantes propriétés de neutralisation. Les anticorps de l'invention sont utilisés pour augmenter la masse osseuse, la densité minérale osseuse et la résistance osseuse et pour traiter des troubles variés, par exemple, l'ostéoporose, chez un sujet humain.
MA32274A 2007-03-20 2009-10-12 Anticorps antisclerostine. MA31308B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (fr) 2007-03-20 2008-03-11 Anticorps antisclérostine

Publications (1)

Publication Number Publication Date
MA31308B1 true MA31308B1 (fr) 2010-04-01

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32274A MA31308B1 (fr) 2007-03-20 2009-10-12 Anticorps antisclerostine.

Country Status (32)

Country Link
US (3) US7744874B2 (fr)
EP (2) EP2664346A1 (fr)
JP (2) JP2010524846A (fr)
KR (1) KR101123487B1 (fr)
CN (1) CN101646457B (fr)
AU (1) AU2008229141B2 (fr)
BR (1) BRPI0809026A2 (fr)
CA (1) CA2682212C (fr)
CO (1) CO6230999A2 (fr)
CR (1) CR11004A (fr)
CY (1) CY1114784T1 (fr)
DK (1) DK2131860T3 (fr)
DO (1) DOP2009000223A (fr)
EA (1) EA018204B1 (fr)
EC (1) ECSP099658A (fr)
ES (1) ES2446293T3 (fr)
HK (1) HK1138790A1 (fr)
HR (1) HRP20140108T1 (fr)
IL (1) IL200437A0 (fr)
MA (1) MA31308B1 (fr)
MX (1) MX2009010051A (fr)
MY (1) MY149129A (fr)
NZ (1) NZ578870A (fr)
PL (1) PL2131860T3 (fr)
PT (1) PT2131860E (fr)
RS (1) RS53157B (fr)
SI (1) SI2131860T1 (fr)
SV (1) SV2009003374A (fr)
TN (1) TN2009000383A1 (fr)
UA (1) UA96474C2 (fr)
WO (1) WO2008115732A2 (fr)
ZA (1) ZA200906345B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2350454T3 (es) 1998-11-27 2011-01-24 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
WO2008115732A2 (fr) * 2007-03-20 2008-09-25 Eli Lilly And Company Anticorps antisclérostine
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
HRP20240722T1 (hr) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
BR112012025568A2 (pt) 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
JP2013525294A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー インプラント骨結合を改善するための方法および組成物
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011159704A1 (fr) * 2010-06-14 2011-12-22 Vaccinex, Inc. Anticorps anti-vegf et utilisations de ceux-ci
SG10201505624VA (en) 2010-11-05 2015-09-29 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
WO2012118903A2 (fr) 2011-03-01 2012-09-07 Amgen Inc. Agents liants bispécifiques
MX338078B (es) 2011-03-25 2016-04-01 Amgen Inc Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
PT2699261T (pt) 2011-04-19 2018-10-22 Amgen Inc Método para tratamento da osteoporose
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
PL2739311T3 (pl) 2011-08-04 2018-08-31 Amgen Inc. Metoda leczenia szczelinowych uszkodzeń kości
EP2771360A1 (fr) * 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique dirigés contre la sclérostine
MX2014004981A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra tnf.
PE20142245A1 (es) 2011-10-24 2015-01-22 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf e il-17
WO2013101451A1 (fr) 2011-12-28 2013-07-04 Amgen Inc. Méthode de traitement d'une perte osseuse alvéolaire au moyen d'anticorps anti-sclérostine
WO2014006100A1 (fr) 2012-07-05 2014-01-09 Ucb Pharma S.A. Traitement de maladies osseuses
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (fr) 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102489471B1 (ko) * 2014-12-30 2023-01-18 셀진 코포레이션 항-cd47 항체 및 그 용도
AU2016232897B2 (en) * 2015-03-13 2021-05-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
IL261200B2 (en) 2016-03-01 2023-03-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2017310412A1 (en) 2016-08-08 2019-02-21 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
KR20190052137A (ko) * 2016-10-28 2019-05-15 일라이 릴리 앤드 캄파니 항-rankl 항체 및 그의 용도
CA3041684C (fr) * 2016-11-01 2023-09-26 Anaptysbio, Inc. Anticorps diriges contre la mort programmee 1 (pd -1)
HRP20210207T4 (hr) * 2016-12-21 2025-01-31 Mereo Biopharma 3 Limited Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta
EP4219563A3 (fr) 2017-01-09 2023-10-04 Tesaro, Inc. Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
WO2018139623A1 (fr) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
WO2018227187A1 (fr) * 2017-06-09 2018-12-13 The Regents Of The University Of California Pro-gélateurs peptidiques cycliques injectables par cathéter pour l'ingénierie tissulaire myocardique
TW201909913A (zh) 2017-07-27 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種ｓｏｓｔ抗體醫藥組成物及其用途
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
AU2019316575A1 (en) 2018-08-10 2021-03-04 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
WO2020154150A1 (fr) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux à haute affinité ciblant le glypicane-1 et procédés d'utilisation
EP4013786A1 (fr) 2019-08-12 2022-06-22 Amgen Inc. Formulations d'anticorps anti-sclérostine
WO2025019728A1 (fr) 2023-07-19 2025-01-23 Amgen Inc. Procédés de préparation d'une solution tampon pour une formulation protéique thérapeutique
CN119097708A (zh) * 2024-09-04 2024-12-10 中国医学科学院北京协和医院 Dkk1抗体在治疗男性骨质疏松症中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350454T3 (es) 1998-11-27 2011-01-24 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2001098491A2 (fr) 2000-06-19 2001-12-27 F. Hoffmann-La Roche Ag Polymorphismes genetiques d'osteolevine
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (fr) * 2002-11-27 2004-06-10 Visiopharm Aps Procede et systeme permettant d'etablir une mesure quantitative d'une destruction articulaire
AU2004262640B2 (en) * 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005005604A2 (fr) 2003-06-30 2005-01-20 Centocor, Inc. Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
AU2004324464A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008115732A2 (fr) * 2007-03-20 2008-09-25 Eli Lilly And Company Anticorps antisclérostine

Also Published As

Publication number Publication date
MY149129A (en) 2013-07-15
AU2008229141A1 (en) 2008-09-25
ES2446293T3 (es) 2014-03-07
US7744874B2 (en) 2010-06-29
PL2131860T3 (pl) 2014-05-30
HRP20140108T1 (hr) 2014-02-28
EA200970874A1 (ru) 2010-02-26
US7988970B2 (en) 2011-08-02
CO6230999A2 (es) 2010-12-20
CA2682212A1 (fr) 2008-09-25
SV2009003374A (es) 2011-01-10
HK1138790A1 (en) 2010-09-03
SI2131860T1 (sl) 2014-02-28
MX2009010051A (es) 2009-10-12
WO2008115732A3 (fr) 2008-12-11
EP2131860A2 (fr) 2009-12-16
ECSP099658A (es) 2009-10-30
CN101646457A (zh) 2010-02-10
NZ578870A (en) 2012-01-12
US20110250205A1 (en) 2011-10-13
UA96474C2 (en) 2011-11-10
DK2131860T3 (da) 2014-01-13
JP5758933B2 (ja) 2015-08-05
CA2682212C (fr) 2014-05-06
CR11004A (es) 2009-11-02
IL200437A0 (en) 2010-04-29
JP2010524846A (ja) 2010-07-22
RS53157B (en) 2014-06-30
KR101123487B1 (ko) 2012-03-23
ZA200906345B (en) 2010-11-24
JP2013151504A (ja) 2013-08-08
US8257704B2 (en) 2012-09-04
WO2008115732A2 (fr) 2008-09-25
US20090060924A1 (en) 2009-03-05
DOP2009000223A (es) 2009-10-15
BRPI0809026A2 (pt) 2014-09-23
EP2131860B1 (fr) 2013-12-18
EA018204B1 (ru) 2013-06-28
US20100221263A1 (en) 2010-09-02
KR20090114462A (ko) 2009-11-03
AU2008229141B2 (en) 2013-02-07
EP2664346A1 (fr) 2013-11-20
CY1114784T1 (el) 2016-12-14
TN2009000383A1 (en) 2010-12-31
CN101646457B (zh) 2013-05-01
PT2131860E (pt) 2014-03-04

Similar Documents

Publication Publication Date Title
MA31308B1 (fr) Anticorps antisclerostine.
LTPA2022520I1 (fr)
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
MX2007000026A (es) Anticuerpos monoclonales quimericos y humanizados contra interleucina-13.
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
TW200736274A (en) Immunoglobulins
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
TNSN04078A1 (fr) Antibodies to cd40
MY149630A (en) Antibodies against amyloid-beta peptide
GEP20104922B (en) Antibodies to m-csf
UA117807C2 (uk) ІМУНОКОН&#39;ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ
MA28982B1 (fr) Anticorps antagonistes de il-17
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
MX2009006891A (es) Anticuerpos cd44.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2007042309A3 (fr) Generation et profilage d&#39;anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
HK1119712A1 (en) Anti-il-23 antibodies
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EP3345925A3 (fr) Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés
WO2009000929A3 (fr) Composition et procédé de traitement de maladie auto-immune
MA38161A1 (fr) Anticorps anti-bmp-6